Trial · NCT07881783
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
NCT07881783, Not yet recruiting, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy. Trials, record NCT07881783. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881783
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
- NCT number
- NCT07881783
- Status
- Not yet recruiting
- Enrollment
- 3,718 participants, estimated
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Plaque Psoriasis
- First posted
- 2026-10-19
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Secukinumab Treatment Discontinuation During the First 12 Months of Follow-up | 12 months | |
| Secondary | Number of Patients by Demographic and Clinical Characteristics | Baseline | Demographics and clinical characteristics include: * Age group * Sex * Race/ethnicity * Geographic region * Insurance type * Psoriatic arthritis diagnosis * Comorbidities * Prior treatments |
| Secondary | Duration of PsO Disease | Baseline | |
| Secondary | Number of Healthcare Visits | Baseline | Healthcare visits include hospitalizations, outpatient/physician visits, and emergency department visits. |
| Secondary | Proportion of Days Covered (PDC) for Secukinumab | 6, 12, and 24 months | Adherence will be measured using PDC. PDC: the number of days with secukinumab available divided by the total number of days in the observation period. Adherence will be categorized as high (PDC ≥80%), medium (PDC 50-79%), or low (PDC \<50%). |
| Secondary | Percentage of Patients Remaining on Secukinumab Treatment at 6, 12, and 24 Months After Secukinumab Initiation | 6, 12, and 24 months | |
| Secondary | Time to Secukinumab Treatment Discontinuation | Up to approximately 11 years | |
| Secondary | Number of Healthcare Visits Per Patient-Year (PPY) | Up to approximately 11 years | Healthcare resource utilization will include all-cause and PsO-related hospitalizations, emergency department visits, and outpatient visits, where identifiable. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881783
GET https://conductscience.org/api/trials/v1/NCT07881783/registered